Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

von Minckwitz, Gunter; Huang, Chiun-Sheng; Mano, Max S; Loibl, Sibylle; Mamounas, Eleftherios P; Untch, Michael; Wolmark, Norman; Rastogi, Priya; Schneeweiss, Andreas; Redondo, Andres; Fischer, Hans H; Jacot, William; Conlin, Alison K; Arce-Salinas, Claudia; Wapnir, Irene L; Jackisch, Christian; DiGiovanna, Michael P; Fasching, Peter A; Crown, John P; Wülfing, Pia; Shao, Zhimin; Rota Caremoli, Elena; Wu, Haiyan; Lam, Lisa H; Tesarowski, David; Smitt, Melanie; Douthwaite, Hannah; Singel, Stina M; Geyer, Charles E.

N Engl J Med ; 380(7): 617-628, 2019 02 14.

Artículo en Inglés | MEDLINE | ID: mdl-30516102

2.

What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.

Wright, Bill J; Conlin, Alison K; Allen, Heidi L; Tsui, Jennifer; Carlson, Matthew J; Li, Hsin Fang.

Cancer ; 122(5): 791-7, 2016 Mar 01.

Artículo en Inglés | MEDLINE | ID: mdl-26650571

3.

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.

Moore, Halle C F; Barlow, William E; Somlo, George; Gralow, Julie R; Schott, Anne F; Hayes, Daniel F; Kuhn, Peter; Hicks, James B; Welter, Lisa; Dy, Philip A; Yeon, Christina H; Conlin, Alison K; Balcueva, Ernie; Lew, Danika L; Tripathy, Debasish; Pusztai, Lajos; Hortobagyi, Gabriel N.

Clin Cancer Res ; 28(4): 611-617, 2022 02 15.

Artículo en Inglés | MEDLINE | ID: mdl-34844978

4.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.

Chun, Brie; Pucilowska, Joanna; Chang, ShuChing; Kim, Isaac; Nikitin, Benjamin; Koguchi, Yoshinobu; Redmond, William L; Bernard, Brady; Rajamanickam, Venkatesh; Polaske, Nathan; Fields, Paul A; Conrad, Valerie; Schmidt, Mark; Urba, Walter J; Conlin, Alison K; McArthur, Heather L; Page, David B.

J Immunother Cancer ; 10(1)2022 01.

Artículo en Inglés | MEDLINE | ID: mdl-35086949

5.

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer.

Page, David B; Pucilowska, Joanna; Sanchez, Katherine G; Conrad, Valerie K; Conlin, Alison K; Acheson, Anupama K; Perlewitz, Kelly S; Imatani, James H; Aliabadi-Wahle, Shaghayegh; Moxon, Nicole; Mellinger, Staci L; Seino, Amanda Y; Martel, Martiza; Wu, Yaping; Sun, Zhaoyu; Redmond, William L; Rajamanickam, Venkatesh; Waddell, Dottie; Laxague, Deborah; Shah, Monil; Chang, Shu-Ching; Urba, Walter J.

Clin Cancer Res ; 26(7): 1595-1605, 2020 04 01.

Artículo en Inglés | MEDLINE | ID: mdl-31831558

6.

Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.

Conlin, Alison K; Seidman, Andrew D.

Clin Breast Cancer ; 8(3): 215-23, 2008 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-18650151

7.

Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.

Janelsins, Michelle C; Heckler, Charles E; Peppone, Luke J; Kamen, Charles; Mustian, Karen M; Mohile, Supriya G; Magnuson, Allison; Kleckner, Ian R; Guido, Joseph J; Young, Kelley L; Conlin, Alison K; Weiselberg, Lora R; Mitchell, Jerry W; Ambrosone, Christine A; Ahles, Tim A; Morrow, Gary R.

J Clin Oncol ; 35(5): 506-514, 2017 Feb 10.

Artículo en Inglés | MEDLINE | ID: mdl-28029304

8.

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

Smith, John W; Buyse, Marc E; Rastogi, Priya; Geyer, Charles E; Jacobs, Samuel A; Patocskai, Erica J; Robidoux, André; Conlin, Alison K; Ansari, Bilal; Keogh, George P; Stella, Philip J; Gross, Howard M; Lord, Raymond S; Polikoff, Jonathan A; Mauquoi, Celine; Mamounas, Eleftherios P; Swain, Sandra M; Wolmark, Norman.

Clin Breast Cancer ; 17(1): 48-54.e3, 2017 02.

Artículo en Inglés | MEDLINE | ID: mdl-27693116

9.

Dermatological toxicity of ixabepilone.

Conlin, Alison K; Vahdat, Linda.

Anticancer Res ; 26(3B): 2279-80, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-16821602

10.

Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

Seidman, Andrew D; Conlin, Alison K; Bach, Ariadne; Moynahan, Mary Ellen; Lake, Diana; Forero, Andres; Wright, Gail Shaw; Hackney, Mary Helen; Clawson, Alicia; Norton, Larry; Hudis, Clifford A.

Clin Breast Cancer ; 13(4): 239-246.e1, 2013 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-23829890

11.

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

Conlin, Alison K; Seidman, Andrew D; Bach, Ariadne; Lake, Diana; Dickler, Maura; D'Andrea, Gabriella; Traina, Tiffany; Danso, Michael; Brufsky, Adam M; Saleh, Mansoor; Clawson, Alicia; Hudis, Clifford A.

Clin Breast Cancer ; 10(4): 281-7, 2010 Aug 01.

Artículo en Inglés | MEDLINE | ID: mdl-20705560

12.

Taxanes in breast cancer: an update.

Conlin, Alison K; Seidman, Andrew D.

Curr Oncol Rep ; 9(1): 22-30, 2007 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-17164044

13.

Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.

Conlin, Alison K; Seidman, Andrew D.

Mol Diagn Ther ; 11(6): 355-60, 2007.

Artículo en Inglés | MEDLINE | ID: mdl-18078353

14.

Point: combination versus single-agent chemotherapy: the argument for sequential single agents.

Conlin, Alison K; Seidman, Andrew D.

J Natl Compr Canc Netw ; 5(8): 668-72, 2007 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-17927924

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer.

Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.

Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

Dermatological toxicity of ixabepilone.

Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

Taxanes in breast cancer: an update.

Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.

Point: combination versus single-agent chemotherapy: the argument for sequential single agents.